BioVaxys Shares New Data on its DPX(TM) Immune Educating Platform at Personalized Cancer Vaccine Summit

Stock Information for BioVaxys Technology Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioVaxys Technology Corp.

BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT OFFERING FOR GROSS PROCEEDS OF UP TO $3,000,000
BioVaxys Technology Corp. Granted Management Cease Trade Order
BioVaxys Announces Debt Settlement Agreement, Extension of Private Placement Closing Date and Closing of The Fourth and Final Tranche of Private Placement
BIOVAXYS ANNOUNCES EXTENSION OF PRIVATE PLACEMENT CLOSING DATE
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT
BIOVAXYS ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT AND ANNOUNCES DEBT SETTLEMENT AGREEMENT

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.